№ files_lp_4_process_3_087366
File format: docx
Character count: 13287
File size: 42 KB
Supplementary source providing quantitative data on DHCR24 expression and its association with clinical characteristics, survival outcomes, and experimental procedures in bladder cancer research.
Year:
2026
Region / City:
Guangzhou, China
Subject:
Molecular biology / oncology
Document type:
Supplementary data tables
Institution:
Igebio, Takara, Cell Signaling Technology, Abcam
Authors:
Research team at Igebio and affiliated institutions
Target audience:
Biomedical researchers, oncologists
Patient cohort:
296 BCa patients
Methods:
qRT-PCR, western blot, immunofluorescence, siRNA transfection, lentivirus infection, ELISA
Analyzed genes:
DHCR24, GAPDH, TBK1, VEGF-C, LAMC2, PCK2, SGK3, FGF7, TP53, IGF2, DDIT4, THBS3, NRAS, UBC9
Statistical analysis:
Chi-square test, Cox regression
Period of study:
Not specified
Supplementary tables:
S1–S5
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Study type:
Supplementary material
Cohort size:
93 patients
Disease:
Metastatic melanoma
Methods:
Multiplex immunofluorescence, image cytometry, Cox regression, LASSO analysis
Data type:
Tables and figures
Variables analyzed:
Clinicopathologic characteristics, cell density, proximity measurements, immune biomarkers
Statistical software:
R
Target population:
Patients with metastatic melanoma
Follow-up period:
5 years
Document type:
Supplementary tables
Subject:
Epidemiology, clinicopathology and diagnostic testing of herpesvirus infections
Species affected:
Domestic goose (Anser anser domestics); Black swan (Cygnus atratus)
Locations:
Lowood; Townsville; Maryborough; Lockyer Valley; Cairns
Dates covered:
15/01/1989–5/01/2021; 14/02/1991 (swan case)
Number of cases:
6
Number at risk:
159 geese; 4 swans
Number dead:
141 geese; 2 swans
Clinical signs:
Lethargy, recumbency, inappetence, vomiting, diarrhoea, tremors, ataxia, open-mouth breathing, rapid death
Gross pathology findings:
Hepatic petechiae and necrosis, splenomegaly, intestinal plaques and haemorrhages, thymic enlargement, pulmonary congestion
Histopathology findings:
Multifocal necrotising hepatitis, splenitis, enteritis, thymitis, vasculitis, eosinophilic intranuclear inclusion bodies
Diagnostic methods:
PCR, virus isolation, electron microscopy, next generation sequencing, serology, microbiology, ELISA
Viruses identified:
Goose herpesvirus (AnHV-2); distinct herpesvirus (AnHV-3)
GenBank accession numbers:
OR578703; OR578701; OR540300; OR578702; OR578704
Comparative tests performed:
Avian Influenza Type A, Newcastle disease virus, DVE, DHV1, pigeon herpesvirus, rotavirus, Salmonella, botulism, heavy metals
Note:
Year
Topic:
Cancer diagnosis
Document Type:
Audit tool
Target Audience:
Healthcare professionals involved in cancer diagnostics
Contextual description:
A diagnostic audit tool for evaluating and improving the capacity of healthcare services in delivering a timed HPB cancer diagnostic pathway.
Year:
2016
Region / city:
United Kingdom
Topic:
Medical imaging, Radiation dose reduction
Document Type:
Guidelines
Organization / institution:
Royal College of Radiologists, British Association of Urological Surgeons
Author:
Dr. John Maguire, Nicola Spence, Dr. Karen Gray
Target Audience:
Radiologists, CT radiographers
Effective Period:
Ongoing
Approval Date:
28 January 2016
Last Reviewed:
8 April 2018
Year:
2025
Region / City:
Leicester, Leicestershire and Rutland
Topic:
Bowel and bladder care for children and young people
Document Type:
Official correspondence
Organization / Institution:
Leicester, Leicestershire and Rutland Integrated Care Board (LLR ICB)
Author:
Corporate Governance Team, LLR ICB
Target Audience:
Public and relevant healthcare professionals
Period of Validity:
Not specified
Approval Date:
27 May 2025
Date of Modifications:
Not specified
Year:
Not specified
Region / city:
Not specified
Subject:
Neoplastic lesions, surgical resection
Document type:
Medical report
Institution:
Not specified
Author:
Not specified
Target audience:
Medical professionals, pathologists
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Note:
Context
Year:
2023
Region / city:
Not specified
Topic:
Functional Gall Bladder Disease, Cholecystectomy, Gall Bladder Pain
Document Type:
Research Article
Author:
Not specified
Target Audience:
Medical professionals, researchers
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2020
Region / City:
Neuquén, Argentina
Topic:
Gynecologic cancer, radiotherapy, dose optimization
Document type:
Research article
Organization / Institution:
Centro Oncológico Integral, Fundación Médica de Río Negro y Neuquén
Authors:
M. Bertero, R. González Armesto, J. De Brida, M. S. Gallo, R. Ruggeri
Target Audience:
Medical professionals, oncologists, researchers in radiotherapy
Period of validity:
N/A
Approval date:
N/A
Date of modifications:
N/A
Procedure Code:
CPT 51715
Procedure Name:
Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck
Clinical Indication:
Stress urinary incontinence in women
Population:
Women with stress urinary incontinence
Evidence Sources:
Cochrane Review (Kirchin 2012); NICE 2005; NICE 2019; American Urology Association 2017; Syan 2016; MODA 2019; Aetna 2019
Study Types Referenced:
Randomized controlled trials; case series; systematic review; guideline statements
Comparators:
Conservative treatment; placebo injection; surgical management; pelvic floor muscle training
Reported Outcomes:
Continence rates; quality of life; patient satisfaction; adverse events; objective cure
Adverse Events Reported:
Urinary tract infection; urinary retention; dysuria; abscess; urgency of micturition; prolonged pain; haemorrhage; migration of bulking agent; allergic reaction
Regulatory Reference:
FDA-cleared bulking agents listed (Coaptite, Contigen, Durasphere, Macroplastique, Uryx)
Coverage Criteria:
Prior conservative management; defined duration of symptoms; documented improvement after initial treatments; limitation on number of injections
Guideline Recommendations:
Consider in patients unsuitable for or declining surgery; counseling on limited long-term efficacy and potential need for repeat injections
Review Date Mentioned:
August 2019
Year:
2023
Region / city:
Global
Subject:
Bladder Cancer, Diagnostic Tests
Document Type:
Systematic Review and Meta-Analysis
Author:
Unspecified
Target Audience:
Researchers, Healthcare Professionals
Period of Validity:
2023
Date of Approval:
2023
Date of Changes:
Not specified
Supplementary Material:
Yes
Methodology:
PRISMA 2020 Checklist
Data Sources:
Databases, Registers, Websites, Organisations
Risk of Bias Assessment:
Included Studies
Statistical Methods:
Meta-Analysis, Heterogeneity Assessment
Results:
Statistical Synthesis, Sensitivity Analysis
Conflicts of Interest:
Unspecified
Funding:
Unspecified
Data Availability:
Publicly Available
Supplementary Figures:
Flow Charts
Year:
2020
Region / City:
Not specified
Subject:
Bladder cancer, radical radiotherapy, cystoscopy
Document Type:
Audit Template
Organization:
Not specified
Author:
Dr. Richard Walshaw, Dr. Tony Elliott
Target Audience:
Urologists, Radiotherapy professionals, Clinical Nurse Specialists
Period of Action:
Not specified
Approval Date:
14 March 2020
Review Date:
22 May 2020
Year:
2024
Region / city:
Philadelphia, Pennsylvania, United States of America
Theme:
Neuroscience, Rehabilitation, Motor Function Restoration
Document Type:
Research Dataset
Institution / Organization:
Aging + Cardiovascular Discovery Center at the Lewis Katz School of Medicine, Temple University
Author:
Mary F Barbe, PhD
Target Audience:
Researchers, Academics, Medical Professionals
Period of Activity:
2016-2023
Date of Approval:
2024
Date of Changes:
Not specified
Year:
2026
Region / city:
Global
Topic:
Urinary bladder cancer, risk factors, dietary intake
Document type:
Supplementary material
Organization:
N/A
Author:
N/A
Target audience:
Researchers in oncology, public health professionals
Effective period:
N/A
Approval date:
N/A
Date of changes:
N/A
Year:
2026
Region:
International
Topic:
Medical research / Urology
Document type:
Search strategy
Institution:
Not specified
Author:
Not specified
Target audience:
Medical researchers and clinicians
Keywords:
ORC, LRC, RARC, bladder tumor, bladder cancer, minimally invasive, robotic surgery
Date created:
2026-03-09
Year:
2024
Region / City:
Zhanjiang, Guangdong Province, China
Topic:
Bladder cancer, TM9SF1
Document type:
Editorial
Organization:
Guangdong Medical University, The Marine Biomedical Research Institute
Authors:
Shu-Qing Zhou, Lian-Xiang Luo
Target audience:
Researchers, healthcare professionals
Period of validity:
Not specified
Approval date:
January 30, 2024
Date of revisions:
December 27, 2023
Date of receipt:
December 9, 2023
Date of publication:
In press
Keywords:
Bladder cancer, TM9SF1, Cell proliferation, Migration, Invasion, Overexpression, Silencing
Core tip:
TM9SF1, a member of the transmembrane 9 superfamily, promotes bladder cancer cell growth and movement, potentially offering a new target for BC treatment.
TM9SF1 function:
Oncogene in bladder cancer
Experimental methods:
CCK8, wound healing test, transwell migration test, flow cytometry
Research focus:
Investigating the role of TM9SF1 in bladder cancer progression
Note:
Contextual description
Year:
2026
Region / City:
N/A
Subject:
Oncology, Urology
Document Type:
Case Report
Organization / Institution:
N/A
Author:
Alhilaly S, Elbaz R, Khan I
Target Audience:
Healthcare professionals, researchers in urology and oncology
Period of validity:
N/A
Approval Date:
N/A
Date of amendments:
N/A